What are the investment strengths of Halozyme Therapeutics Inc (HALO)?

Asset-light royalty model generates 59% operating margin and 30% ROIC TTM - capital efficiency far exceeds biotech peers at 0% median margin 5Y EPS CAGR 42% and revenue CAGR 40% demonstrate durable growth from expanding partner pipeline without proportional cost increases

What are the investment risks for Halozyme Therapeutics Inc (HALO)?

Debt/equity 3.0x with 711M current debt due - refinancing risk if rates stay elevated or partner revenues disappoint Concentrated partner dependency - revenue tied to few pharma licensees creates binary risk if key drugs underperform

Halozyme Therapeutics Inc

HALO

—

Build a strategy around HALO

Halozyme Therapeutics Inc AI Insights

Informational only. Not investment advice.

As of 2025-12-17

Snapshot

ROE of 124% TTM vs industry median -39% driven by asset-light royalty model with 59% operating margin on 1.2B revenue[Return on Equity]
Tangible book value -261M with goodwill 83% of equity (417M vs 504M) - intangible-heavy balance sheet[Tangible Book Value]
FCF of 602M TTM (48% margin) with capex under 9M - near-pure cash conversion from royalty streams[Free Cash Flow]

Watch Triggers

Current Debt: Refinancing terms or extension of 711M due — Near-term debt maturity could pressure liquidity if capital markets tighten
Operating Margin: Decline below 50% — Would signal royalty mix shift or cost creep eroding model advantage
Accounts Receivable: Growth exceeding revenue growth — Rising AR/revenue ratio could indicate partner payment delays

Bull Case

Asset-light royalty model generates 59% operating margin and 30% ROIC TTM - capital efficiency far exceeds biotech peers at 0% median margin

Operating MarginROICFree Cash Flow

5Y EPS CAGR 42% and revenue CAGR 40% demonstrate durable growth from expanding partner pipeline without proportional cost increases

EPS Growth 5YRevenue Growth 5Y

Bear Case

Debt/equity 3.0x with 711M current debt due - refinancing risk if rates stay elevated or partner revenues disappoint

Debt to EquityCurrent DebtTotal Debt

Concentrated partner dependency - revenue tied to few pharma licensees creates binary risk if key drugs underperform

Total RevenueAccounts Receivable

Bull vs Bear Balance

AI-generated sentiment analysis based on fundamental metrics and market conditions.

60%

Leverage HALO's top insights and create a custom strategy based on them in seconds. Our AI editor does it all — in one click.

Take Me to The Editor

Forward Thesis

Royalty-driven FCF will accelerate as ENHANZE partners scale commercial launches

1-3ymed

48% FCF margin with minimal reinvestment needs
5Y revenue CAGR 40% vs industry 7%
Operating leverage from fixed cost base

FCF 602M TTM on 1.2B revenueCapex only 9M (0.7% of revenue)Operating margin 59% vs industry 0%

Valuation Context

Caveats

Public Strategies Rankings

See how Halozyme Therapeutics Inc ranks across different investment strategies.

Leverage HALO's top insights and create a custom strategy in seconds. Our AI editor does it all — in one click.

HALO Fundamentals

Manufacturing → Chemical Manufacturing

Metric	Value	YoY Growth	Industry Percentile
Market Cap	$7.89B		—
Enterprise Value	$9.89B		—
P/E Ratio	25		—
Total Revenue - TTM	$1.4B	+37.6%	—
Earnings Per Share (diluted) - TTM	$2.56	+30.9%	—
Operating Margin - TTM	57.5%	+3.2%	—
Net Margin - TTM	22.7%	-21.0%	—
Free Cash Flow - TTM	$356.82M	-23.8%	—
Return on Common Equity - TTM	154%	-44.8%	—
Beta 5Y (Monthly)	unknown		—

HALO Dividend History

No dividends

HALO Stock Splits

No stock splits

HALO SEC Filings

Filing Date	Report Date	Report Type	Filing Link
02/17/26	12/31/25	10-K	0001159036-26-000024
11/03/25	09/30/25	10-Q	0001159036-25-000045
08/05/25	06/30/25	10-Q	0001159036-25-000034
05/06/25	03/31/25	10-Q	0001159036-25-000026
02/18/25	12/31/24	Unknown	0001159036-25-000010
10/31/24	09/30/24	10-Q	0001159036-24-000050
08/06/24	06/30/24	10-Q	0001159036-24-000044
05/07/24	03/31/24	10-Q	0001159036-24-000037
02/20/24	12/31/23	10-K	0001159036-24-000008
11/06/23	09/30/23	10-Q	0001159036-23-000057
08/08/23	06/30/23	10-Q	0001159036-23-000048
05/09/23	03/31/23	10-Q	0001159036-23-000039
02/21/23	12/31/22	10-K	0001159036-23-000012
11/08/22	09/30/22	10-Q	0001159036-22-000059
08/09/22	06/30/22	10-Q	0001159036-22-000050
05/10/22	03/31/22	10-Q	0001159036-22-000038
02/22/22	12/31/21	10-K	0001159036-22-000014
11/02/21	09/30/21	10-Q	0001159036-21-000050
08/09/21	06/30/21	10-Q	0001159036-21-000043
05/10/21	03/31/21	10-Q	0001159036-21-000038
02/23/21	12/31/20	10-K	0001159036-21-000014
11/02/20	09/30/20	10-Q	0001159036-20-000044
08/10/20	06/30/20	10-Q	0001159036-20-000037
05/11/20	03/31/20	10-Q	0001159036-20-000030
02/24/20	12/31/19	10-K	0001159036-20-000013
11/12/19	09/30/19	10-Q	0001159036-19-000060
08/06/19	06/30/19	10-Q	0001159036-19-000044
05/07/19	03/31/19	10-Q	0001159036-19-000027
02/21/19	12/31/18	10-K	0001159036-19-000006
11/06/18	09/30/18	10-Q	0001159036-18-000043
08/07/18	06/30/18	10-Q	0001159036-18-000037
05/10/18	03/31/18	10-Q	0001159036-18-000031
02/20/18	12/31/17	10-K	0001159036-18-000011
11/07/17	09/30/17	10-Q	0001159036-17-000045
08/08/17	06/30/17	10-Q	0001159036-17-000038
05/09/17	03/31/17	10-Q	0001159036-17-000030
02/28/17	12/31/16	10-K	0001159036-17-000014
11/07/16	09/30/16	10-Q	0001159036-16-000133
08/09/16	06/30/16	10-Q	0001159036-16-000125
05/09/16	03/31/16	10-Q	0001159036-16-000117
02/29/16	12/31/15	10-K	0001159036-16-000100
11/09/15	09/30/15	10-Q	0001159036-15-000092
08/10/15	06/30/15	10-Q	0001159036-15-000079
05/11/15	03/31/15	10-Q	0001159036-15-000064
03/02/15	12/31/14	10-K	0001159036-15-000041
11/10/14	09/30/14	10-Q	0001159036-14-000093
08/11/14	06/30/14	10-Q	0001159036-14-000070
05/12/14	03/31/14	10-Q	0001159036-14-000042
02/28/14	12/31/13	10-K	0001159036-14-000033
11/08/13	09/30/13	10-Q	0001159036-13-000011
08/07/13	06/30/13	10-Q	0001483813-13-000085
05/08/13	03/31/13	10-Q	0001483813-13-000051
03/01/13	12/31/12	10-K	0001483813-13-000033
11/08/12	09/30/12	10-Q	0001193125-12-460700
08/09/12	06/30/12	10-Q	0001193125-12-345733
05/07/12	03/31/12	10-Q	0001193125-12-215311
03/12/12	12/31/11	10-K	0001193125-12-107555
11/08/11	09/30/11	10-Q	0001193125-11-302232
08/05/11	06/30/11	10-Q	0000950123-11-073693
05/06/11	03/31/11	10-Q	0000950123-11-046096
03/11/11	12/31/10	10-K	0000950123-11-024465
11/05/10	09/30/10	10-Q	0000950123-10-101221
08/06/10	06/30/10	10-Q	0000950123-10-073690
05/07/10	03/31/10	10-Q	0000950123-10-045990
03/12/10	12/31/09	10-K	0000950123-10-023869
11/06/09	09/30/09	10-Q	0000950123-09-058718
08/07/09	06/30/09	10-Q	0000950123-09-031517
05/08/09	03/30/09	10-Q	0000950134-09-010048
03/13/09	12/31/08	10-K	0000950134-09-005273
11/07/08	09/30/08	10-Q	0000950134-08-019741
08/08/08	06/30/08	10-Q	0000950134-08-014666
05/09/08	03/30/08	Unknown	--
03/14/08	12/31/07	10-K	0000936392-08-000196
11/09/07	09/30/07	10-Q	0000950134-07-023461
08/09/07	06/30/07	10-Q	0000936392-07-000666
05/10/07	03/30/07	Unknown	--
03/09/07	12/31/06	10-K	0000936392-07-000182
11/09/06	09/30/06	10-Q	0000936392-06-001037
08/08/06	06/30/06	10-Q	0000936392-06-000776
05/10/06	03/30/06	Unknown	--
12/31/05	12/31/05	10KSB	0000936392-06-000262
09/30/05	09/30/05	10QSB	0000936392-05-000385
06/30/05	06/30/05	10QSB	0000950137-05-009868
03/31/05	03/31/05	8-K	0000950137-05-003895
12/31/04	12/31/04	5	0001181431-05-007918
09/30/04	09/30/04	10QSB	0000950137-04-009837
06/30/04	06/30/04	10QSB	0000950137-04-006797
05/13/05	03/30/04	10QSB	0000950137-05-005955
05/14/04	03/30/04	10QSB	0001144204-04-006584
03/30/04	12/31/03	10KSB	0001144204-04-003771
11/14/03	09/30/03	10QSB	0001144204-03-007347
08/14/03	06/30/03	10QSB	0001188915-03-000024
05/19/03	03/30/03	10QSB	0001189306-03-000313
03/31/03	12/31/02	10KSB	0001189306-03-000193
11/14/02	09/30/02	10QSB	0001163765-02-000468
08/19/02	06/30/02	10QSB	0001163765-02-000356
05/15/02	03/30/02	10QSB	0001163765-02-000149